Michelle Drozd, deputy vice president of PhRMA’s Policy and Research department, says value-based contracts can help cut out-of-pocket costs and grant patients access to “the right treatments the first time.”
“Recent criticisms of value-based contracts — or results-based contracts — are off base in questioning whether these contracts are having an impact on drug and health care sending,” Drozd writes.
Below are four key facts about value-based contracts, according to Drozd:
- Value-based deals can reduce out-of-pocket costs for patients;
- Scores of stakeholders are actively pursuing results-based deals;
- Numerous biopharmaceutical companies are pursuing value-based deals; and
- Barriers often prevent value-based agreements.
To read Drozd’s full break down of value-based contracts, click here.